Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
- 1 February 1998
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 351 (9102), 543-549
- https://doi.org/10.1016/s0140-6736(97)04161-5
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic MillimeterNew England Journal of Medicine, 1996
- Zidovudine Alone or in Combination with Didanosine or Zalcitabine in HIV-Infected Patients with the Acquired Immunodeficiency Syndrome or Fewer Than 200 CD4 Cells per Cubic MillimeterNew England Journal of Medicine, 1996
- Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individualsThe Lancet, 1996
- A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 InfectionNew England Journal of Medicine, 1995
- A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 ProteaseNew England Journal of Medicine, 1995
- Didanosine Compared with Continued Zidovudine Therapy for HIV-Infected Patients with 200 to 500 CD4 Cells/mm^3: A Double-Blind, Randomized, Controlled TrialAnnals of Internal Medicine, 1995
- A Controlled Trial of Zidovudine in Primary Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1995
- ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.Proceedings of the National Academy of Sciences of the United States of America, 1995
- Zidovudine in Persons with Asymptomatic HIV Infection and CD4+ Cell Counts Greater than 400 per Cubic MillimeterNew England Journal of Medicine, 1993
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987